<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR013033</article-id>
      <title-group>
        <article-title>PROSPECTIVE PROCESS VALIDATION OF GLICLAZIDE TABLET</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Deshmukh</surname>
            <given-names>Onkar J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lahoti</surname>
            <given-names>Swaroop R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rajendra</surname>
            <given-names>Vivek B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gulecha</surname>
            <given-names>Bhushan S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rawat</surname>
            <given-names>Pavan Kumar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>kulkarni</surname>
            <given-names>Snehal A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Sherya Life Sciences, B9/2, MIDC Wlauj, Aurangabad-431136</aff>
      <aff id="aff2">Y.B.Chavan College of Pharmacy, Dr.Rafiq Zakaria Campus, Rauza Bagh, Aurangabad-01.</aff>
      <aff id="aff3">JSPM’s Jayawantrao Sawant College of Pharamcy and Research, Hadapsar, Pune-28.</aff>
      <pub-date pub-type="epub" iso-8601-date="2011-10-01">
        <month>10</month>
        <day>01</day>
        <year>2011</year>
      </pub-date>
      <volume>1</volume>
      <issue>3</issue>
      <abstract>
        <p>  The objective of designing a dosage form is to achieve predictable therapeutic response to a drug included in a formulation which is capable of large scale manufacture with reproducible product quality. In order to ensure quality of product various features are required, like chemical and physical stability, preservation against microbial contamination, uniformity of dose of drug, acceptability to users including prescriber and patient, as well as suitable packing, labeling, and validation. The present research work focused on prospective process validation for the gliclazide 40mg tablet. Tablet was manufactured by wet granulation method. Formulation of tablet using Maize Starch, Avicel Ph 102, PVP-K30, sodium starch glycolate, Purified Talc, Aerosil 200 and  Magnesium stearate. Uniformity of dry mixing is excellent in 10min because % RSD found to be 0.4267-0.9021%. Granulating agent was prepared of desired consistency. Drying time 30 min is sufficient to achieve LOD 2-3%. Evaluation parameter of sizing shows effective LOD, % fine, BD &amp; CI. Lubrication stage uniformity was achieved with 10min because % RSD found 0.8320-1.032% and flow properties was satisfactory. Compression machines optimum speed (20RPM) was satisfactory for effective compression. Based on results at each of the stages for the specified parameters it is concluded that gliclazide tablets can be effectively prepared with the desired specification &amp; reproducible quality standards.  </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Prospective Validation</kwd>
        <kwd>Gliclazide</kwd>
        <kwd>Tablet.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
